Advanced Liver Cancer clinical trials

Explore recruiting advanced liver cancer clinical trials.

Recruiting advanced liver cancer studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Liver Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Is CT 01 safe to use alone or combined with Everolimus for inoperable advanced liver cancer?

France, Spain, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A first-in-human study to learn about the safety of BAY 3547926 and how well it works in participants with advanced liver cancer

Spain, Belgium, Finland, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A study to assess the safety and anti-tumor activity of T cell therapy in subjects with advanced liver cancer or any other AFP expressing tumor types

Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC)

Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)

Romania, Poland, Spain, Czechia, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination with Tremelimumab or Bevacizumab in Subjects with Advanced Hepatocellular Carcinoma

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Advanced Liver Cancer trials by city

Advanced Liver Cancer clinical trials

Recruiting advanced liver cancer studies right now

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)

OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer

A Study of MGC026 in Participants With Advanced Solid Tumors

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib

Also recruiting in Europe

Is CT 01 safe to use alone or combined with Everolimus for inoperable advanced liver cancer?

A first-in-human study to learn about the safety of BAY 3547926 and how well it works in participants with advanced liver cancer

A study to assess the safety and anti-tumor activity of T cell therapy in subjects with advanced liver cancer or any other AFP expressing tumor types

A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC)

A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)

A Study of Safety, Tolerability, and Clinical Activity of Durvalumab and Tremelimumab Administered as Monotherapy, or Durvalumab in Combination with Tremelimumab or Bevacizumab in Subjects with Advanced Hepatocellular Carcinoma

Advanced Liver Cancer trials by city

Other conditions